FASEB J. Avanti Polar Lipids
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.07-8472com.
(The FASEB Journal. 2007;21:3450-3457.)
© 2007 FASEB
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
fj.07-8472comv1
21/13/3450    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S. S.
Right arrow Articles by Wang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S. S.
Right arrow Articles by Wang, H.

Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells

Soo Sun Lee*, Wenda Gao{dagger}, Silvia Mazzola{ddagger}, Michael N. Thomas*, Eva Csizmadia*, Leo E Otterbein*, Fritz H. Bach* and Hongjun Wang*,1

* Departments of Surgery and

{dagger} Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA and

{ddagger} Dipartimento di Patologia animale, Universita degli Studi di Milano, Italy

1Correspondence: Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Ave., Boston, MA 02215 USA. E-mail: hwang3{at}bidmc.harvard.edu

Heme oxygenase-1 (HO-1) induction in, or carbon monoxide (CO), or bilirubin administration to, donors and/or recipients frequently lead to long-term survival (>100 days) of DBA/2 islets into B6AF1 recipients. We tested here whether similar treatments show value in a stronger immunogenetic combination, i.e., BALB/c to C57BL/6, and attempted to elucidate the mechanism accounting for tolerance. Induction of HO-1, administering CO or bilirubin to the donor, the islets or the recipient, prolonged islet allograft survival to different extents. Combining all the above treatments (the "combined" protocol) led to survival for >100 days and antigen-specific tolerance to 60% of the transplanted grafts. A high level of forkhead box P3 (Foxp3) and transforming growth factor ß (TGF-ß) expression was detected in the long-term surviving grafts. With the combined protocol, significantly more T regulatory cells (Tregs) were observed surrounding islets 7 days following transplantation. No prolongation of graft survival was observed using the combined protocol when CD4+CD25+ T cells were predepleted from the recipients before transplantation. In conclusion, our combined protocol led to long-term survival and tolerance to islets in the BALB/c to C57BL/6 combination by promoting Foxp3+ Tregs; these cells played a critical role in the induction and maintenance of tolerance in the recipient.—Lee, S. S., Gao, W., Mazzola, S., Thomas, M. N., Csizmadia, E., Otterbein, L. E., Bach, F. H., and Wang, H. Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells.


Key Words: islet transplantation • allograft survival




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
P. Blancou and I. Anegon
Editorial: Heme oxygenase-1 and dendritic cells: what else?
J. Leukoc. Biol., February 1, 2010; 87(2): 185 - 187.
[Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Biburger, G. Theiner, M. Schadle, G. Schuler, and G. Tiegs
Pivotal Advance: Heme oxygenase 1 expression by human CD4+ T cells is not sufficient for their development of immunoregulatory capacity
J. Leukoc. Biol., February 1, 2010; 87(2): 193 - 202.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Sakaguchi, K. Wing, Y. Onishi, P. Prieto-Martin, and T. Yamaguchi
Regulatory T cells: how do they suppress immune responses?
Int. Immunol., October 1, 2009; 21(10): 1105 - 1111.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
R. Hernandez-Pando, D. Aguilar, H. Orozco, Y. Cortez, L. R. Brunet, and G. A. Rook
Orally Administered Mycobacterium vaccae Modulates Expression of Immunoregulatory Molecules in BALB/c Mice with Pulmonary Tuberculosis
Clin. Vaccine Immunol., November 1, 2008; 15(11): 1730 - 1736.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. F. George, A. Braun, T. M. Brusko, R. Joseph, S. Bolisetty, C. H. Wasserfall, M. A. Atkinson, A. Agarwal, and M. H. Kapturczak
Suppression by CD4+CD25+ Regulatory T Cells Is Dependent on Expression of Heme Oxygenase-1 in Antigen-Presenting Cells
Am. J. Pathol., July 1, 2008; 173(1): 154 - 160.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The Federation of American Societies for Experimental Biology.